The trial reached equally its Principal endpoints, with semaglutide 2.four mg demonstrating statistically considerable and superior enhancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH when compared with placebo.oneQuite a few patter